Precision Therapy for Brain Tumors in Hereditary Syndromes

Gerald E. Wallace, Madeleine Tjoelker, Kaitlyn Bartley, John W. Henson

Research output: Contribution to journalReview articlepeer-review

Abstract

Nervous system tumors arising in the setting of monogenic, hereditary cancer predisposition syndromes are unique in that the initiating genetic event in tumor formation is known. This knowledge provides a powerful treatment approach if the alteration or pathway can be targeted with a therapeutic agent. A reasonable argument can be made for the use of targeted agents in these tumor patients, even though many of them have FDA approval only for other tumor types. It is our practice to use and employ targeted therapy when standard treatments have failed or represent an unattractive option. Over time, however, targeted therapies will likely become first-line options.

Original languageEnglish (US)
Article number80
JournalCurrent treatment options in oncology
Volume22
Issue number9
DOIs
StatePublished - Sep 2021
Externally publishedYes

Keywords

  • Brain tumor
  • Genetic
  • Hereditary
  • Precision
  • Targeted

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Precision Therapy for Brain Tumors in Hereditary Syndromes'. Together they form a unique fingerprint.

Cite this